CRANBURY, N.J., Feb. 6, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the ...
CRANBURY, N.J., Feb. 7, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) ("Palatin" or the "Company"), a biopharmaceutical company developing ...
Erkunden Sie die legendären Sieben Hügel Roms mit dieser atemberaubenden Drohnenaufnahme und fangen Sie die Schönheit jedes ...
Palatin (PTN) Technologies announced that it has entered into definitive agreements with a single healthcare focused institutional investor for the purchase and sale of 4,688,000 shares of its ...
(RTTNews) - Palatin Technologies, Inc. (PTN) Friday announced that it has entered into agreements with a healthcare-focused institutional investor for the sale of 4.6 million shares at $1.00 each ...
Palatin (PTN) announced topline data for the BREAKOUT study, a Phase IIb study of bremelanotide in diabetic kidney disease. The study showed that bremelanotide therapy for six months, in patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback